The company has received an order for the company's 3D BIO printer BIO X of 3.5 MSEK. The order comes from the company's distributor in Germany, I&L Biosystems.
The order is planned to be delivered mainly during the fourth quarter of the company and is a result of increased demand from the European market.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: +46 73 267 00 00 Phone: +46 70 991 86 04
This information is such that CELLINK AB is required to publish under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on May 11th. 16.45 CET.
CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser.